Panel-based next-generation sequencing facilitates the characterization of childhood acute myeloid leukemia in clinical settings

Hisashi Ishida, Akihiro Iguchi, Michinori Aoe, Ritsuo Nishiuchi, Takehiro Matsubara, Dai Keino, Masashi Sanada, Akira Shimada

Research output: Contribution to journalArticlepeer-review

Abstract

Acute myeloid leukemia (AML) accounts for ~20% of pediatric leukemia cases. The prognosis of pediatric AML has been improved in recent decades, but it trails that of most other types of pediatric cancer, with mortality rates of 30-40%. Consequently, newer more targeted drugs are required for incorporation into treatment plans. These newer drugs selectively target AML cells with specific gene alterations. However, there are significant differences in genetic alterations between adult and pediatric patients with AML. In the present study, inexpensive and rapid next-generation sequencing (NGS) of >150 cancer-related genes was performed for matched diagnostic, remission and relapse (if any) samples from 27 pediatric patients with AML. In this analysis, seven genes were recurrently mutated. KRAS was mutated in seven patients, NRAS was mutated in three patients, and KIT, GATA1, WT1, PTPN11, JAK3 and FLT3 were each mutated in two patients. Among patients with relapsed AML, six harbored KRAS mutations at diagnosis; however, four of these patients lost these mutations at relapse. Additionally, two genetic alterations (FLT3-ITD and TP53 alterations) were detected among patients who eventually relapsed, and these mutations are reported to be adverse prognostic factors for adult patients with AML. This panel-based, targeted sequencing approach may be useful in determining the genetic background of pediatric AML and improving the prediction of treatment response and detection of potentially targetable gene alterations. RAS pathway mutations were highly unstable at relapse; therefore, these mutations should be chosen as a target with caution. Incorporating this panel-based NGS approach into the clinical setting may allow for a patient-oriented strategy of precision treatment for childhood AML.

Original languageEnglish
Article number46
Pages (from-to)1-10
Number of pages10
JournalBiomedical Reports
Volume13
Issue number5
DOIs
Publication statusPublished - 2020

Keywords

  • Acute myeloid leukemia
  • Key leukemia
  • Molecular genetics
  • Pediatric
  • Precision medicine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Panel-based next-generation sequencing facilitates the characterization of childhood acute myeloid leukemia in clinical settings'. Together they form a unique fingerprint.

Cite this